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A 42 year old woman (G5 P3+1 twin pregnancy) presented for
routine antenatal morphology ultrasound scan at 20 weeks. Ultra-
sound also demonstrated an incidental, solitary, 10 cm mass in the
left retroperitoneum. Fine needle cytology revealed indeterminate spin-
dle cells. The retroperitoneal mass did not change on close ultrasound
surveillance and gestation progressed normally. Elective Caesarian
section was scheduled at term with further investigation of the ret-
roperitoneal lesion planned for the postnatal period. Past medical
history was unremarkable except for one episode of gastrointestinal
haemorrhage (capsule endoscopy, upper GI endoscopy and colonoscopy
all negative) requiringmultiple blood transfusions four years prior to the
pregnancy.
At 36 weeks the patient presented with spontaneous, painless
haematochezia and severe anaemia (Hb 56 g/L reference range
110–114 g/L) in combination with fulminating pre-eclampsia. Healthy
twinswere delivered by emergency Caesarian section. After delivery ac-
tive rectal bleeding continued requiring aggressive resuscitation and
transfusion. Nuclear labelled red blood cell scan showed brisk, active
bleeding in the midabdomen and blood pooling in jejunal loops. Angi-
ography conﬁrmed bleeding from a hypervascular left retroperitoneal
mass fed by multiple left sided aortic branches. Extravasation into the
duodenum was noted. Several attempts at angiographic embolization⁎ Corresponding author.
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heterogeneous vascular lesion eroding into the small bowel. The abnor-
mal mass displaced the psoas medially, the left kidney posteriorly and
the third part of the duodenum anteriorly (Fig. 1).
Urgent exploratory laparotomy was undertaken because of ongoing
haemodynamic instability. At the operation, small bowel loops were
distended with sanguineous ﬂuid but no free intraperitoneal blood
was present. A 10 cm highly vascular cystic retroperitoneal mass was
seen to emanate from the third part of the duodenum (Fig. 2). A com-
plete resection of the lesion with histologically clear margins was
performed with primary closure of the duodenal defect. No meta-
static disease was evident at the operation or during subsequent CT
staging investigations. The patient went on to make an uneventful
recovery.
Pathology reported a 120 mm encapsulated GIST containing
areas of haemorrhage. The spindle cell neoplasm arose from
muscularis propria of the duodenum and contained prominent, di-
lated vascular channels with foci suspicious for vascular invasion.
Surgical margins were clear of tumour. Mitotic index was low (1/40
high powered ﬁeld). Immunohistochemical markers were positive
for CD117 and DOG1 and negative for CD34, PDGFR, desmin and
S100.
GIST is a gastrointestinal tract neoplasm derived from precursors of
interstitial cells of Cajal (Tran et al., 2005; Goldblum, 2002). Although
GIST is the most frequent mesenchymal tumour of the digestive tract,
it is still uncommon with an incidence of 6.5–14.5 per million (Tran et
al., 2005). 46% of GIST patients are female and median age at diagnosis
is 55 to 65 years (Tran et al., 2005). In females within the reproductive
ages the tumour is rare. Two thirds of GISTs are derived from the stom-
ach, one quarter from the small bowel and the remainder from the
colon, rectum and oesophagus (Folgado Folgado et al., 2008; Goldblum,
2002). Four cases of GIST in pregnancy have been reported and all in-
volved either the stomach or the small bowel (Barry, 2009; Scherjon et
al., 2009; Valente et al., 1996). Common presentations of GIST include
haemorrhage, anaemia and abdominal mass although many are discov-
ered incidentally (Goldblum, 2002). Previously GIST detected incidental-
ly on antenatal ultrasound scan has been misdiagnosed as both ovarian
and adnexal in pathology (Valente et al., 1996; Scherjon et al., 2009;
Barry, 2009).
Biological behaviour of GIST ranges from indolent to aggressive
and all GIST >2 cm are considered to have malignant potential. Prog-
nostication for primary tumours is based on molecular biomarkers,icense.
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Fig. 1. A CT scan showing the GIST tumour displacing the kidney, the psoas muscle and the 3rd part of the duodenum.
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presence of metastasis (Tran et al., 2005; Folgado et al., 2008;
Goldblum, 2002). Small bowel GISTs are considered to have the
highest risk of metastatic progression (Goldblum, 2002). Most GISTs
have activating mutations in KIT (75–80%) or PDGFRA (5–10%)
(Folgado et al., 2008; Goldblum, 2002; Tran et al., 2005). Overall the
5 year survival rate for GIST patients is 42% (Tran et al., 2005). Of
the four previously reported cases of GIST in pregnancy, three pa-
tients survived a minimum of nine years post diagnosis despite
presenting with metastatic disease (Barry, 2009; Scherjon et al.,
2009; Valente et al., 1996). The case presented here suggests that
GIST had been in situ at least four years prior to diagnosis as obscure
gastrointestinal haemorrhage was ﬁrst investigated in the patient at
that time.
GIST is predominantly managed with surgery and tyrosine kinase
inhibitors as conventional chemotherapy and radiotherapy areFig. 2. An intra-operative photograph of the tumour.ineffective. Surgery aims at complete tumour removal and is general-
ly safe in pregnancy. Tyrosine kinase inhibitors (TKIs) such as
imatinib mesylate are approved for use in recurrent, unresectable or
metastatic GIST. TKI's have shown a marked improvement in survival
(Perez et al., 2006). However imatinib and its metabolites occur in ac-
tive concentrations in maternal blood, placenta and breast milk
(Russel et al., 2007). There are reports of spontaneous abortions and
birth defects following periconception or intrauterine exposure to
imatinib (Ault et al., 2006). As a result TKIs are contra-indicated in
pregnancy and breastfeeding (Wolf and Rumpold, 2009).
In patients with a history of GI bleeding and pelvic/abdominal
mass, a GIST tumour should be considered in addition to other tu-
mours of GI origin. Given the difﬁculties, pregnant patients with
GIST are best managed by a multidisciplinary team with expertise in
GI tumours and foetal–maternal medicine.
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